Table 1.
Patient characteristics.
| Age (years) | Range | 11–64 |
| Mean | 32.1 | |
| Median | 32 | |
| Sex;n(%) | Male | 36 (64%) |
| Female | 20 (36%) | |
| Site of primary tumor;n(%) | Femur | 24 (43%) |
| Tibia | 6 (11%) | |
| Humerus | 7 (13%) | |
| Rib/scapula | 5 (9%) | |
| Other/unidentified bone site | 14 (25%) | |
| Stage;n(%) | IA | 7 (12%) |
| IB | 4 (7%) | |
| IIA | 14 (25%) | |
| IIB | 22 (39%) | |
| III | 3 (5%) | |
| IV | 5 (9%) | |
| Unidentified | 1 (2%) |
Analysis of RANKL and RANK was determined within distinct compartments, including tumor tissue, infiltrating cells, and adjacent normal bone tissue when present. The H-score distributions for RANKL or RANK selectively within OS tumor cells are shown in Fig. 4. The staining distributions for RANKL or RANK within normal bone or infiltrating (nontumor) cells were noted without quantitative scoring. OS, osteosarcoma; RANK, receptor activator of nuclear factor kappa-B; RANKL, RANK ligand.